Drug updated on 4/26/2024
| Dosage Form | Injection (intravenous; 100 mg/10 mL) |
| Drug Class | Interleukin-5 antagonist monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Summary
- Reslizumab (Cinqair) is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older who have an eosinophilic phenotype. It has shown significant efficacy in reducing asthma exacerbation rates and improving lung function.
- Seven systematic reviews/meta-analyses were analyzed to examine the safety and effectiveness of Reslizumab.
- Compared to other biologics such as mepolizumab, benralizumab, and dupilumab, all drugs were superior to placebo in preventing rates of asthma exacerbation, with no significant differences among them for patients with eosinophilic asthma. However, some studies suggested potential higher efficacy for Reslizumab in certain measurements, like improvements in Asthma Control Questionnaire scores.
- A considerable emphasis has been placed on investigating Reslizumab's effects on those inadequately controlled by standard therapies. Indirect comparisons suggest its beneficial role defined by specific eosinophil counts or previous exacerbation history, indicating the need for personalized management strategies based on patient selection criteria.
- Studies emphasize real-world effectiveness, confirming similar effect sizes to randomized controlled trials but also highlight possible inconsistencies due to retrospective data, suggesting a need for more accurate estimates across varied patient subpopulations.
- While Reslizumab offers promising results, especially among individuals suffering from severe eosinophilic asthma, there is still heterogeneity within study populations, which underscores the importance of further research into defining optimal patient population groups benefiting most from this drug regimen.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cinqair (reslizumab) Prescribing Information. | 2019 | Teva Respiratory, LLC, West Chester, PA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Guidance for administering biologics for severe asthma and allergic conditions. | 2022 | Canadian Respiratory Journal |
| EAACI Biologicals Guidelines—Recommendations for severe asthma. | 2021 | Allergy |
| Global strategy for asthma management and prevention. | 2020 | Global Initiative for Asthma |
| Severe asthma: adding new evidence – Latin American Thoracic Society. | 2020 | ERJ Open Research |
| Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. | 2020 | European Respiratory Journal |
| Asthma management guidelines. | 2020 | The National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group |